Accessibility Menu
Kardigan logo

Kardigan

(NASDAQ) KARD

Current Price$21.19
Market Cap$2.05BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)-0%
5 YearN/A
1 YearN/A
1 MonthN/A
Kardigan last closing stock price
MetricPriceDate
Last closeUSD 21.992026-07-15
Kardigan stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.04%USD 22.222026-07-08
Since inception-0.05%USD 22.002026-06-18

Kardigan Financials at a Glance

Market Cap

$2.05BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$74.09

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-8.72 (Low)

Price

$21.19

Volume

378,167.062

Open

$22.00

Previous Close

$21.02

Daily Range

$20.51 - $22.95

52-Week Range

$16.00 - $27.00

Estimated Earnings Date

N/A

KARD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kardigan

Kardigan, Inc. is a clinical-stage precision therapeutics company focused on developing innovative medicines for specific cardiovascular diseases lacking approved treatments. The company is committed to addressing unmet medical needs through its advanced clinical programs.

Products and Services
  • Danicamtiv: A novel therapeutic targeting heart muscle function
  • Ataciguat: A treatment aimed at improving blood flow
  • Tonlamarsen: A precision medicine for cardiovascular conditions
Growth Outlook
  • Market potential for cardiovascular therapeutics is projected to exceed $50 billion
  • Strong pipeline with multiple candidates in advanced clinical stages
  • Strategic partnerships expected to enhance research and development capabilities
Financial Highlights
  • Market capitalization stands at approximately $1.93 billion
  • Stock price has fluctuated between $16.25 and $23.75 in the past year
  • Average trading volume of 5.8 million shares indicates strong investor interest
Kardigan, Inc. operates in the biotechnology sector, specifically targeting cardiovascular diseases with no existing treatments. The company's innovative approach and focus on precision medicine position it well within a growing market. With a robust pipeline and strategic partnerships, Kardigan is poised for significant growth. The recent stock performance reflects investor confidence, as evidenced by the trading volume and market capitalization. Overall, Kardigan represents a compelling opportunity in the healthcare industry.
AI Generated • Jun 20, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

241

CEO

Tassos Gianakakos, MBA

Website

www.kardigan.bio

Headquarters

Princeton, NJ 08540, US

KARD Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$2.05BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

93.09M

Volume

378.17K

Avg. Volume

819.10K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Kardigan Performance Analysis

Kardigan annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Kardigan annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD -0.99N/A
20252025-12-31USD -2.15116.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$2.11

N/A

Gross Margin

N/A

N/A

Market Cap

$2.05BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

241

N/A

Net Income

-$56.07

N/A

EBITDA

-$56.60

N/A

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$95.46

N/A

Total Debt

$13.92

N/A

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$10.25

N/A

Short Term Debt

$3.66

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-$57.94

N/A

Operating Cash Flow

-$56.78

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,531.75-0.01%
^DJIDJI
$52,488.88-0.00%
^IXICNASDAQ
$25,933.85-0.01%
BTCBitcoin
$64,171.00-0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$15.60-0.00%
ATAIAtaiBeckley
$7.15+0.33%
NOKNokia
$10.38-0.08%
ONDSOndas
$6.65-0.06%

Questions About KARD

What is the current price of Kardigan?

Kardigan is trading at $21.02 per share.

What is the 52-week range for Kardigan?

Over the past 52 weeks, Kardigan has traded between $16.00 and $27.00.

How much debt does Kardigan have?

As of the most recent reporting period, Kardigan reported total debt of $13.92M.

How much cash does Kardigan have on hand?

Kardigan reported $81.55M in cash and cash equivalents in its most recent financial results.

What is Kardigan’s dividend yield?

Kardigan does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services